Aquestive Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$5.2M
Doctors Paid
1,926
Transactions
8,110
2024 Total
$5,489
Payment Breakdown by Category
Research$4.3M (83.3%)
Consulting$173,340 (3.3%)
Food & Beverage$144,731 (2.8%)
Travel$67,163 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.3M | 457 | 83.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $473,740 | 328 | 9.1% |
| Consulting Fee | $173,340 | 159 | 3.3% |
| Food and Beverage | $144,731 | 6,703 | 2.8% |
| Travel and Lodging | $67,163 | 459 | 1.3% |
| Grant | $3,000 | 2 | 0.1% |
| Honoraria | $2,925 | 1 | 0.1% |
| Education | $1,250 | 1 | 0.0% |
Payments by Type
Research
$4.3M
457 transactions
General
$866,148
7,653 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| SAFETY AND TOLERABILITY STUDY OF DIAZEPAM BUCCAL SOLUBLE FILM DBSF IN SUBJECTS WITH EPILEPSY | $875,397 | 0 | 81 |
| A PHASE 1, OPEN-LABEL, PARTIALLY RANDOMIZED ADAPTIVE DOSING CROSSOVER STUDY TO COMPARE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EPINEPHRINE FOLLOWING ADMINISTRATION OF TWO FORMULATIONS OF DIPIVEFRIN SUBLINGUAL FILM AND EPINEPHRINE ADMINISTERED AS INTRA | $332,909 | 1 | 3 |
| Safety and Tolerability Study of Diazepam Buccal Soluble Film (DBSF) in Subjects With Epilepsy (DBSF) | $295,043 | 0 | 83 |
| A RANDOMIZED, OPEN-LABEL, TWO-SEQUENCE, TWO-PERIOD, TWO-TREATMENT CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF VALTOCO DIAZEPAM NASAL SPRAY IN HEALTHY ADULT SUBJECTS | $230,576 | 1 | 7 |
| Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy | $191,936 | 1 | 26 |
| UNDERSTANDING PATIENT PERCEPTIONS AND PREFERENCES FOR DIFFERENT ROUTES OF ADMINISTRATION FOR CLUSTER SEIZURE TREATMENT | $168,495 | 1 | 15 |
| AN OPEN-LABEL, SAFETY AND TOLERABILITY STUDY OF CHRONIC INTERMITTENT USE OF DIAZEPAM BUCCAL FILM DBF IN PEDIATRIC, ADOLESCENT AND ADULT SUBJECTS WITH EPILEPSY | $137,050 | 1 | 13 |
| A MULTICENTER, OPEN-LABEL, CROSSOVER STUDY TO ASSESS THE PHARMACOKINETICS AND SAFETY OF DIAZEPAM BUCCAL FILM DBF IN PEDIATRIC SUBJECTS WITH EPILEPSY | $127,997 | 1 | 14 |
| Assessment of Pharmacokinetics and Safety of Diazepam Buccal Soluble Film in Pediatric Patients (DBSF) | $110,646 | 0 | 23 |
| ASSESSMENT OF PHARMACOKINETICS AND SAFETY OF DIAZEPAM BUCCAL SOLUBLE FILM IN PEDIATRIC PATIENTS DBSF | $93,858 | 0 | 18 |
| ASSESSMENT OF PHARMACOKINETICS AND SAFETY OF DIAZEPAM BUCCAL SOLUBLE FILM IN PEDIATRIC PATIENTS | $74,525 | 0 | 13 |
| SAFETY AND TOLERABILITY STUDY OF DIAZEPAM BUCCAL SOLUBLE FILM DBSF IN SUBJECTS WITH EPILEPSY DBSF | $19,246 | 0 | 6 |
| STUDY OF DIAZEPAM BUCCAL FILM ADMINISTERED IN THE INTERICTAL AND IN THE ICTAL-PERIICTAL STATES TO ADULTS WITH EPILEPSY | $13,571 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Gary Slatko, Md, MD | Internal Medicine | New York, NY | $910,320 | $0 |
| Paul Mullin, Md, MD | Neurology | New York, NY | $141,562 | $0 |
| Maxine Ingham, Md, MD | Internal Medicine | Las Vegas, NV | $120,352 | $0 |
| Pavel Klein, Md, MD | Neurology | Bethesda, MD | $70,430 | $0 |
| Jesus Pina-Garza, Md, MD | Neurology | Nashville, TN | $49,574 | $0 |
| Dr. Michael Rogawski, M.d, M.D | Neurology | Sacramento, CA | $42,038 | $0 |
| Dr. Sami Aboumatar, M.d, M.D | Neurology | Austin, TX | $31,433 | $0 |
| Atiya Khan, M.d, M.D | Neurology | Fort Wayne, IN | $28,235 | $0 |
| Dr. Allen Heller, M.d, M.D | Internal Medicine | Woodbridge, CT | $27,700 | $0 |
| Rotem Elgavish, Md, Phd, MD, PHD | Epilepsy | Lone Tree, CO | $27,138 | $0 |
| Mark Lepore, Md, MD | Family Medicine | Lawrence, MA | $24,505 | $0 |
| Dr. Nabil Azar, Md, MD | Clinical Neurophysiology | Nashville, TN | $23,711 | $0 |
| David Rogawski, Md, MD | Neurology | Stanford, CA | $21,450 | $0 |
| Jose Ferreira, Md, MD | Specialist | Tampa, FL | $21,351 | $0 |
| Dr. David Bernstein, M.d, M.D | Internal Medicine | Cincinnati, OH | $20,666 | $0 |
| Julio Flamini, M.d, M.D | Neurology | Atlanta, GA | $20,267 | $0 |
| Yu-Tze Ng, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Overland Park, KS | $19,976 | $0 |
| Amit Verma, Md, MD | Neurology | Houston, TX | $19,521 | $0 |
| Adriana Tanner, Md, MD | Neurology | Cleveland, OH | $19,000 | $0 |
| Michael Chez, Md, MD | Neurology | Sacramento, CA | $17,279 | $0 |
| Ann Segeren, Md, MD | Epilepsy | Stanford, CA | $16,676 | $0 |
| Raman Sankar, M.d, M.D | Neurodevelopmental Disabilities | Los Angeles, CA | $15,485 | $0 |
| David Golden, M.d, M.D | Allergy | Baltimore, MD | $15,474 | $0 |
| Dr. James Wheless, Md, MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $14,704 | $0 |
| Jong Rho, M.d, M.D | Neurology with Special Qualifications in Child Neurology | New Haven, CT | $13,619 | $0 |
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. has made $5.2M in payments to 1,926 healthcare providers, recorded across 8,110 transactions in the CMS Open Payments database. In 2024, the company paid $5,489. The top product by payment volume is LIBERVANT ($1.5M).
Payments were distributed across 89 medical specialties. The top specialty by payment amount is Internal Medicine ($1.1M to 48 doctors).
Payment categories include: Food & Beverage ($144,731), Consulting ($173,340), Research ($4.3M), Travel & Lodging ($67,163).
Aquestive Therapeutics, Inc. is associated with 3 products in the CMS Open Payments database.